ReviewJournal of gastrointestinal cancer2022

Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review.

Peixin Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.